Glenmark Pharmaceuticals USA to Launch Micafungin for Injection in September 2025

Pharmaceuticals Inc., USA, a subsidiary of Glenmark Pharmaceuticals Ltd., has announced the upcoming launch of Micafungin for Injection USP, available in 50 mg/vial and 100 mg/vial single-dose vials. The product is bioequivalent and therapeutically equivalent to Mycamine® for Injection by Astellas Pharma US, Inc. (NDA-021506). Distribution is set to begin in September 2025. According to IQVIA sales data for the 12-month period ending June 2025, the Mycamine® for Injection market (50 mg/vial and 100 mg/vial) generated approximately $60.7 million in annual sales. Glenmark aims to capture a share of this market by offering a high-quality, affordable alternative for patients requiring antifungal treatment. Marc Kikuchi, President & Business Head, North America, stated, “We are excited to announce the launch of Micafungin for Injection USP, 50 mg/vial and 100 mg/vial (Single-Dose Vial), growing our portfolio of products within the institutional channel, while also strengthening our commitment to bring quality and affordable alternatives to market for patients in need.” Micafungin is used to treat serious fungal infections, including candidemia, acute disseminated candidiasis, candida peritonitis, abscesses, and esophageal candidiasis. This launch further solidifies Glenmark’s presence in the antifungal market and enhances its institutional product portfolio. Glenmark Pharmaceuticals Ltd. is a global leader in pharmaceuticals, with a focus on respiratory, dermatology, and oncology. The company operates 11 world-class manufacturing facilities across four continents and has a presence in over 80 countries. Glenmark is ranked among the Top 100 Companies by R&D and Pharmaceutical Sales in 2022 by In Vivo/Scrip 100 and among the Top 50 Generics and Biosimilars Companies by Sales in 2022 by Generics Bulletin/In Vivo.